

A woman with blonde hair is looking thoughtfully at a molecular model she is holding in her hand. The model consists of black, white, blue, and red spheres connected by white rods. The background is a soft, out-of-focus grey. A dark blue ribbon-like graphic element flows across the top and bottom of the image.

healthcapital

lifecycle investments &
advisory worldwide

Corporate Presentation

- About us
- Biotech Investments
- World Healthcare Policy Advisory
- Strategic Counseling

- Healthcapital SA is an internationally operating biotech investment advisory and healthcare management company.
- Lines of work:
 - Investments into biotech companies which develop new drug candidates and/or eliminate bottlenecks in the drug development process
 - A global healthcare policy advisory think-tank
 - Strategic counseling



Davide Gai

Trained in Medicine and Business 20 years experience in high tech startups and strategic consulting. Serial high technology entrepreneur.

Carlo M. Croce, *MD*

Professor of Medicine, Director Institute of Genetics, Director of Human Cancer Genetics Program, The Ohio State University. Multiple honors/awards for outstanding contributions in cancer research. Editor-in-Chief American Academy Association for Cancer Research.

Ruggero Fariello, *MD*

Former Professor and Chair of Neurology at Rush Medical College of Chicago and JMC. Founder of Neuron SpA, which was successfully listed at the Swiss Stock Market.

Joseph S. Gonnella, *MD*

Dean of Jefferson Medical College in Philadelphia from 1984 to 2000. Has managed world-class scientists and million dollars of research grants. Is advising a number of countries, including China, to reconstruct their medical education and healthcare system.

Richard A. Insel, *MD*

Executive Vice President of Research at the Juvenile Diabetes Research Foundation (JDRF). Serves on the National Advisory Allergy and Infectious Diseases Council of the NIH. Co-founder of Praxis Biologics.

Georg Friedrich (Fritz) Melchers, *PhD, Dr. h.c mult.*

Professor for Immunology at University of Basel. Former director of Basel Institute for Immunology. Co-founder of 4-Antibody Ltd., serves as a scientific advisor and on the Board of Directors of the Company.

Roger James Pomerantz, *MD, FACP*

Professor for Medicine at Jefferson Medical College Philadelphia. President Tibotec Pharmaceuticals Inc Global Therapeutic Area Head of Virology, Senior Vice President Johnson and Johnson, Inc.

Richard A. Insel, MD

Executive Vice President of Research at the Juvenile Diabetes Research Foundation (JDRF). Serves on the National Advisory Allergy and Infectious Diseases Council of the NIH. Co-founder of Praxis Biologics.

Georg Friedrich (Fritz) Melchers, PhD, Dr. h.c mult.

Professor for Immunology at University of Basel. Former director of Basel Institute for Immunology. Co-founder of 4-Antibody Ltd., serves as a scientific advisor and on the Board of Directors of the Company.

Roger James Pomerantz, MD, FACP

Professor for Medicine at Jefferson Medical College Philadelphia. President Tibotec Pharmaceuticals Inc Global Therapeutic Area Head of Virology, Senior Vice President Johnson and Johnson, Inc.

GUIDING PRINCIPLE


- Healthcapital SA actively sources internationally for privately-held companies world wide that are creating new product opportunities and next generation technologies that address real unmet medical needs. We have a significant focus on biopharmaceutical companies with proprietary compounds or technologies that have the potential to become new therapies. We target preferentially high growth biotech businesses that have the potential to deliver return of 3 times or more of the principal investment in 5 years time frame.
- We aim to balance the levels of risk and to focus on the timing of returns, with a considerable emphasis on investments with low risk and the potential for early returns. These investments will be matched with a portion of the portfolio consisting of innovative companies with a potential of very high returns. We typically aim to have the life cycle of investment in a company, that is, from the time we make the first investment to the company's exit, in the range of 3 -5 years.

INDUSTRY FOCUS

- **Biopharmaceutical Companies**
with proprietary compounds or products that have the potential to become new therapeutics. While we will consider any exciting biotech investment opportunity, we particularly focus on ONC, CNS, TX, immunology, virology, ID, CVS, metabolic diseases, from chemical to biologic compounds.
- **Product Platform Companies**
that use proprietary technologies to discover new drug candidates for internal development and/or partnerships.
- **Medtech Companies**
with cardiovascular, respiratory, and kidney approaches.

Biotech Investments: Investment Focus

	Discovery	Preclinical Studies	IND Filing	Clinical Phase 1	Clinical Phase 2	Clinical Phase 3	NDA Filing	FDA EMEA	Phase 4
Years	2 - 6	3.5		1	2	3		2.5	
Test Population	Laboratory	Laboratory and animal studies		20 to 80 healthy volunteers	100 to 300 healthy volunteers	1000 to 3000 healthy volunteers			
Purpose	Discovery of new chemical/ biological entities	Assess safety and biological activity		Determine safety and dosage	Evaluate effectiveness and side effect	Variety effectiveness and monitor adverse reactions		Review and approval	Post-marketing testing
Cost (UsD mn)				0.1 - 1	10 - 100	10 - 500			
Success Rate	10000	10 - 20		5- 10	2 - 5	2		1	





TeLoRmedix is a Swiss-based biopharmaceutical company formed to develop immunoselective cancer drugs targeting Toll-like Receptors (TLRs) with an initial focus on superficial bladder cancer. TLRs are receptors that modulate the innate immune response. The company focuses on drugs that have been previously tested in humans, have favorable safety profile, and an innovative scientific rationale. This approach allows to rapidly developing drugs designed to be very selective and well tolerated. TeLoRmedix has also exclusively licensed a library of new TLR molecules from the University of California San Diego (UCSD) that have already shown efficacy in preclinical animal models of various diseases.



Founded in April 2006, Speciality European Pharma (SEP) is a privately owned speciality pharmaceutical company. Its mission is to become the leading urologist-focused speciality pharmaceutical business in Europe. SEP owns worldwide rights to Plenaxis®, the first approved GnRH blocker for the treatment of prostate cancer. SEP has distribution rights in certain European countries for two further products Amphocil®, an anti-fungal agent and Haemopressin®, a product for the treatment of Bleeding Oesophageal Varices. SEP has its own commercial operations in the UK, Germany, France, and Italy and will market its products in other regions and territories through relationships with expert partners.



GlobeImmune, Inc., a bio-pharmaceutical company based in Louisville, Colorado, is developing a new type of drugs called Tarmogens for the treatment of cancer and infectious diseases with the potential of significantly impacting patient management. The choice of yeast provides competitive advantages to the company: easy and cost-containing product manufacturing, possibility of repeated administration and high efficacy in stimulating the immune system against a target protein. The safety of these compounds has been demonstrated on more than 200 patients up to now. Two main lines of business, hepatitis C and cancer are pursued with a strong commitment on the oncology program mainly due to the recent deal with Celgene, an overall deal of 500m\$ signed in May 2009. In both business areas Globeimmune collected very positive data from phase II programs and it is ready to start pivotal trials.




VisionCare Ophthalmic Technologies is a privately held specialty medical device company, based in Saratoga (California) engaged in the research, development, manufacture, and marketing of proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders.

The Company's lead product, the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), is the first FDA-approved implantable medical device demonstrated to improve vision and quality of life in individuals with the most advanced, irreversible form of age-related macular degeneration (AMD). End-Stage AMD is one of leading cause of blindness worldwide.

- Biotech investments require a Worldwide extensive network, in order to properly source for companies. Furthermore, healthcare policymakers are important stakeholders for a financial institution to know.
- The World Healthcare Policy Advisory, managed by Healthcapital provides yet another competitive advantage which extends to its shareholders.

World Healthcare Policy Advisory: Global Representation

lifescience investments &
advisory worldwide



- Thanks to its constantly growing worldwide network of key players in health care and drug development, ICT, telecom and banking, Healthcapital SA offers strategic counseling in biotech investments and healthcare management to 3rd parties, such as banks, foundations, institutions and universities, in areas such as:
 - Funds raising
 - Private Equity and M&A
 - In –out licensing
 - Link to Academic Research and Industry Community
 - Intellectual Property assessment and valuation

This publication is for information purposes only and may not be interpreted as an offer, proposal or recommendation to purchase or sell any products. All information contained in the brochure is based on the status as at June 25 2011; products, services and prices are subject to change at any time and without advance notice. In some countries certain products and services are subject to legal restrictions; the information regarding these products is therefore intended for those countries where such restrictions do not apply.

Contacts

Healthcapital SA

Via F. Pelli 2 CH-6900 Lugano / Switzerland

Phone: +41-91-911-8415 Fax: +41-91-911-8414

info@healthcapital.ch

www.healthcapital.ch

Twitter: @healthcapital1